London
· Delayed Price · Currency is GBP · Price in GBXSkinBioTherapeutics Statistics
Total Valuation
SkinBioTherapeutics has a market cap or net worth of GBP 26.85 million. The enterprise value is 24.10 million.
| Market Cap | 26.85M |
| Enterprise Value | 24.10M |
Important Dates
The next estimated earnings date is Friday, November 29, 2024.
| Earnings Date | Nov 29, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
SkinBioTherapeutics has 226.09 million shares outstanding. The number of shares has increased by 11.47% in one year.
| Shares Outstanding | 226.09M |
| Shares Change (YoY) | +11.47% |
| Shares Change (QoQ) | +2.45% |
| Owned by Insiders (%) | 3.63% |
| Owned by Institutions (%) | 39.12% |
| Float | 175.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 128.52 |
| PB Ratio | 6.19 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -8.36 |
| EV / Sales | 149.12 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -7.72 |
Financial Position
The company has a current ratio of 6.57, with a Debt / Equity ratio of 2.66.
| Current Ratio | 6.57 |
| Quick Ratio | 6.48 |
| Debt / Equity | 2.66 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.03 |
| Interest Coverage | -380.12 |
Financial Efficiency
Return on equity (ROE) is -118.64% and return on invested capital (ROIC) is -74.81%.
| Return on Equity (ROE) | -118.64% |
| Return on Assets (ROA) | -61.18% |
| Return on Capital (ROIC) | -74.81% |
| Revenue Per Employee | 14,695 |
| Profits Per Employee | -262,269 |
| Employee Count | 11 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0.89 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.80% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -47.80% |
| 50-Day Moving Average | 11.62 |
| 200-Day Moving Average | 11.55 |
| Relative Strength Index (RSI) | 45.61 |
| Average Volume (20 Days) | 478,913 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SkinBioTherapeutics had revenue of GBP 161,648 and -2.88 million in losses. Loss per share was -0.02.
| Revenue | 161,648 |
| Gross Profit | 101,676 |
| Operating Income | -3.03M |
| Pretax Income | -3.04M |
| Net Income | -2.88M |
| EBITDA | -3.00M |
| EBIT | -3.03M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 2.84 million in cash and 97,050 in debt, giving a net cash position of 2.74 million or 0.01 per share.
| Cash & Cash Equivalents | 2.84M |
| Total Debt | 97,050 |
| Net Cash | 2.74M |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 3.65M |
| Book Value Per Share | 0.02 |
| Working Capital | 2.79M |
Cash Flow
In the last 12 months, operating cash flow was -3.02 million and capital expenditures -104,753, giving a free cash flow of -3.12 million.
| Operating Cash Flow | -3.02M |
| Capital Expenditures | -104,753 |
| Free Cash Flow | -3.12M |
| FCF Per Share | -0.01 |
Margins
| Gross Margin | 62.90% |
| Operating Margin | -1,877.21% |
| Pretax Margin | -1,882.15% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -1,931.00% |
Dividends & Yields
SkinBioTherapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.47% |
| Shareholder Yield | -11.47% |
| Earnings Yield | -13.90% |
| FCF Yield | -11.63% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |